Abstract 139P
Background
Combining local thermal ablation with immune checkpoint inhibitors for small hepatocellular carcinoma is uncharted territory. This phase II trial aimed to evaluate the safety and efficacy of combining thermal ablation with tislelizumab, an anti-PD-1 antibody, in patients with Barcelona Clinic Liver Cancer stage A or B HCC.
Methods
This phase II trial (NCT04652440) included newly diagnosed and recurrent HCC patients with 1 or 2 lesions measuring 2-5 cm. Patients received their first tislelizumab dose intravenously within one day before percutaneous thermal ablation, followed by infusions every three weeks for a total of four doses. Primary endpoints were safety and tolerability. Secondary endpoints included complete response rate by first thermal ablation, local recurrence rate, distant metastasis rate, and 1- and 2-year disease-free survival and overall survival rates. This study was presented as a poster at ESMO Asia 2023 in Singapore, and this is an update on the present study.
Results
The study completed recruiting 30 HCC patients in August 2023. The CR1 was 93.33%, with 26 patients (86.67%) completing the entire treatment. One patient discontinued due to a severe adverse event related to thermal ablation and did not receive further medication, while another switched to resection after a second failed ablation. By the data cut-off on May 27, 2024, 23 patients (76.7%) experienced grade ≥3 treatment-related adverse events. The most common were elevated alanine aminotransferase (N=16) and aspartate aminotransferase (N=23) levels on the first-day post-ablation, with most recovering after supportive treatment. Additionally, 12 patients experienced grade 1-2 immune-related adverse events (irAEs), including rash (N=9), pruritus (N=6), and anorexia (N=4), with no grade ≥3 irAEs reported. One patient developed renal failure six months after the last dose of tislelizumab and was diagnosed with multiple myeloma, likely unrelated to the study treatment. The one-year DFS rate was 71.4% (95% confidence interval, 56.4% to 90.4%).
Conclusions
Combining thermal ablation with tislelizumab showed acceptable safety and tolerability, with no unexpected SAEs. Long-term outcomes will be disclosed in the future.
Clinical trial identification
NCT04652440.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract